FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 347:1703-1705 November 21, 2002 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Koutsky, L. A. Related Article by Stanberry, L. R. PubMed Citation

In this issue of the Journal, Koutsky et al.¹ complete a 20-year odyssey that began with the isolation of the cancer-causing human papillomaviruses (HPVs).^2,3 In 1983, investigators in zur Hausen's laboratory established HPV type 16 (HPV-16) as the leading candidate in the pathogenesis of preinvasive and invasive cervical neoplasia.^2,4 More than 20 types of papillomavirus have now been identified and associated with cervical cancer. A critical property of oncogenic papillomaviruses is the extremely low number of particles of infectious virus detected. This lack of working material stifled early vaccine research, even as researchers solved the intricate puzzle of viral oncogenesis.⁵ . . . [Full Text of this Article]

This article has been cited by other articles:

• Blumenthal, P. D., Gaffikin, L. (2005). Cervical Cancer Prevention: Making Programs More Appropriate and Pragmatic. JAMA 294: 2225-2228 [Full Text]  
• Ng, E., Wilkins, R., Fung, M. F. K., Berthelot, J.-M. (2004). Cervical cancer mortality by neighbourhood income in urban Canada from 1971 to 1996. CMAJ 170: 1545-1549 [Abstract] [Full Text]  
• Goldie, S. J., Kohli, M., Grima, D., Weinstein, M. C., Wright, T. C., Bosch, F. X., Franco, E. (2004). Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine. JNCI J Natl Cancer Inst 96: 604-615 [Abstract] [Full Text]  
• Kulasingam, S. L., Myers, E. R. (2003). Potential Health and Economic Impact of Adding a Human Papillomavirus Vaccine to Screening Programs. JAMA 290: 781-789 [Abstract] [Full Text]  
• Siegelman, E. S. (2003). Invited Commentary. RadioGraphics 23: 981-981 [Full Text]  
• (2003). An HPV Vaccine -- At Last!. JWatch Women's Health 2003: 1-1 [Full Text]  
• (2002). Human Papillomavirus Type 16 Vaccine -- Hope for Protection Against Cervical Cancer. JWatch Infect. Diseases 2002: 6-6 [Full Text]  
• (2002). HPV Vaccine: Harbinger of Immunizations to Come. JWatch Pediatrics 2002: 1-1 [Full Text]  
• (2002). Vaccine Against HPV-16 and, Possibly, Cervical Cancer. JWatch General 2002: 1-1 [Full Text]